Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
For sure an interesting increase. Wonder if it’s due to shortage elsewhere. That question may not be answered until the next cc. I’ll happily wait until then. Nice to see some news before next cc.
News out. Congratulations. In Nasrat We trust. Cheers.
Sorry, I just posted mine before I read yours. I definitely agree up almost 50% from original estimate nice and it’s only gonna keep getting stronger.
On the bright side, I thought the original information given before approval a year ago was only a $42 million market. It’s up almost 50% since then for generic version listed now in the 60 mil
its out, Market cap 63Million
want to thank this forum - it was this weekend where it brought that extra value and smile of expectations...:)
https://www.streetinsider.com/Corporate+News/Elite+Pharmaceuticals%2C+Inc.+%28ELTP%29+Receives+FDA+Approval+for+Generic+Methotrexate/23248959.html
$64 million IQVIA not $42 million. Is it possible this is not the ANDA filed 4-20-23? I know that sales fluctuate from year to year but that is a wide variance. In any case, it’s a nice addition to Elite’s product portfolio.
THX, 64 mill, I was hoping for better, Oh well, it's in shortage, and another quiver for Kirko,
at least it will keep the lights on, and is needed for those doing Chemo.
NORTHVALE, NJ / ACCESSWIRE / May 20, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for generic Methotrexate Sodium 2.5 mg tablets. Methotrexate belongs to a class of drugs known as antimetabolites and will be sold under the Elite Laboratories, Inc. label. IQVIA reported annual sales of $64.3 million for the twelve months ending March 2024 for the generic market for this product.
It’s 7 am. In goat land anyway. Time to wake up and take care of business
Try to relax King👑, it probably won't mean too much "IF" it is even PR'ed !!!!!!!!!!!!!!!!!!!!!!!!
Hey Thanks A Lot King👑,
IB_🤴🏻
Should not be a gap with this one!
The desires in your heart are proof of God's promise to you.
This is a tough one to understand at first, but one piece of the puzzle is Jeremiah 1:5
Hi Nasdaq2020, The Aurobindo product is listed under Eugia ,the ndc number matches.
New article,
https://www.yahoo.com/news/adhd-drug-shortage-shows-signs-120000784.html?fr=sycsrp_catchall
you must read this carefully, they switched her from Vyvanse to Adderall
This is why I say Elite just fell into a 5 billion dollar MKT, by default, or accident.
ANTTHING GOES
Thanks rocio, I'm surprised Kirko hasn't taken over as a spin DR.
I think God has a little more important things to do God is not here to make people filthy rich God did say it would be easier for a camel to pass through the eye of a needle than for a rich man to enter heaven Good luck
I am so happy for you, but realize you make your own miracles as one loves’ oneself and all is connected to the universe of love and acceptance. What you truly think and truly believe create your reality for your avatar in this “self”existence. Situations in this life or meant to teach us lessons to acquire a higher self of love, understanding and acceptance of all - may peace, empathy, and love always be with you and your family. Remember, love and despair are always intermingled to teach us lessons for the higher self.
In 2012 I was told by a person deeply connected to god (who made miracles I could not explain ) that I would be filthy rich.
Just fyi. Today I am comfortable. I expect the buy out will do the rest.
It’s broad day light in goat land. That’s why you can’t sleep lol
Monday’s PPS probably won’t spike a whole lot if past history continues. The approval is excellent and many more to come, but as we have all seen that doesn’t translate to higher PPS immediately. But what it does confirm immediately is the excellent, excellent path the Elite team is taking us on as investors and reconfirming our bright, bright future of prosperity. We are all very, very blessed and lucky to be a part of this ride, but I believe everything in life that happens to you is preconceived and destined so we have all chosen to be here and for this to be happening for us and our families. Buckle up, strap in, lock and load - gonna be a great year and a half to two years on this ride to see where it takes us.
Happiness and good health to all!
Lol. What time zone are you in ? It is after 8am in the Eastern USA.
Can't sleep.
Keep thinking about tomorrow's press release.
Thanks.
Thanks James, guess we wait till tomorrow. lol
Hi Sharkey, the Aurobindo ndc is 59651-0182-01 . Like you, I was trying to find the IQVIA market size. I am not sure if I ever sold Aurobindo brand. The brand that is currently "preferred" on Cardinal is Zydus ndc 68382-0775-01 . Both Zydus and Aurobindo are Indian pharma companies that sell many products in the USA and elsewhere.
Looks like India for Aurobindo .
https://www.marketscreener.com/quote/stock/AUROBINDO-PHARMA-9059028/news/Aurobindo-Pharma-Eugia-Pharma-receives-USFDA-Approval-for-Methotrexate-Tablets-29933007/
Or is it made in India and sold in USA, or world wide, ?
could be the reason I can't find in orange book or on the FDA page.
Found Eugia on the FDA page
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=browseByLetter.page&productLetter=M&ai=0
All this to find a current IQVIA
I’m about to be riiiiiiiiiiich! Soon to be multi million reasons why idgaf about you continually throttling my posting here. Stay mad kid. The new Ferrari says vrrrrooom. 😂😂😂😂🤡🤡🤡
It will be interesting to see the market size indications when the 8k is released on Monday. According to the shortage list, there are 8 other companies that serve the Methotrexate market. Hopefully Elite will launch during next quarter commencing on June 1 and Kirkov can continue his track record of upward trajectory of generic drug sales.
Trexall is one of the branded methotrexate products. Working retail pharmacy I sell generic methotrexate 2.5mg frequently. I can’t recall the last time I sold Trexall or any of the other branded products.
Teva makes the branded Methotrexate
Trexall
I don’t see that Pharma on the shortage list ?
FDA shortage link for Methotrexate
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methotrexate%20Sodium%20Tablet&st=c
The stay was predicated on the pending similar claim brought by Purdue v. ACCORD. If that case is not decided by July 17, the stay will be extended.
***** 15 DAYS - KEEP YOU EYES ON SEC FILINGS *****
Hakim Promissory Note: $3,000,000. The original maturity date of the Hakim Promissory Note is June 2, 2024, with an optional second year extension. The second year extension must be exercised by both parties 60 days prior to the original maturity date.(IT NEVER HAPPENED) As of the date of this filing, the Company does not expect to exercise the second year extension.
Methotrexate tablets market size much larger than $42 million in 2019 according to Aurobindo https://www.aurobindousa.com/news/product-news/aurobindo-receives-fda-approval-for-methotrexate-tablets-usp-2-5-mg. They also just have 2.5 mg tablets. It has gotten less popular but I’m surprised at the size of the drop.
We will have a guessing game for the longs. Thank you!
What the hell are you talking about????
Nasrat is going to jail. You wrote it yourself.
King of my ask!!!
Revenue guessing game begins next month on the day of the conference call press release.
Thanks.
***** 60 DAYS *****
https://www.pacermonitor.com/public/case/51356241/PURDUE_PHARMA_LP_et_al_v_ELITE_LABORATORIES_INC,_et_al
January 17: 6-month stay begins
July 17: 6-months stay ends
Notice how EACH quarter adds a FULL quarter of a NEW drug.
And CY2025 Q1 adds a FULL quarter of TWO new drugs.
We're about to be bought!!!!!!!!!!
CY2024 Q1
1. ✅️ Full quarter of Adderall XR with Prasco
CY2024 Q2
1. ✅️ Full quarter of Adderall XR with Prasco
2. ✅️ Full quarter of Vigabatrin
CY2024 Q3
1. ✅️ Full quarter of Adderall XR with Prasco
2. ✅️ Full quarter of Vigabatrin
3. ✅️ Full quarter of Methotrexate
CY2024 Q4
1. ✅️ Full quarter of Adderall XR with Prasco
2. ✅️ Full quarter of Vigabatrin
3. ✅️ Full quarter of Methotrexate
4. ✅️ Full quarter of Generic Oxycontin
CY2025 Q1
1. ✅️ Full quarter of Adderall XR with Prasco
2. ✅️ Full quarter of Vigabatrin
3. ✅️ Full quarter of Methotrexate
4. ✅️ Full quarter of Generic Oxycontin
5. ✅️ Full quarter of Dopamine Agonist
6. ✅️ Full quarter of Vyvanse
Everyone knows you said this gap would never get filled. Did you delete your messages. Going away for 6 weeks does make your stupidity disappear. LMAO.
Also, I’ll be checking the approvals page come Monday morning.
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=reportsSearch.process
Thanks sharkey.
I tired to link it directly Elite's page but I see now the link doesn't work. Appreciate the help for the board.
Your link does. I search the same way.
I like this page better
https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
Go to search by company. Type in elite, not eltp.
Not sure this would gap up. This isn’t a needle mover, but it is yet another positive step in the right direction. Gives Kirko another to sell and let’s get that new facility moving!
Followers
|
960
|
Posters
|
|
Posts (Today)
|
10
|
Posts (Total)
|
400318
|
Created
|
03/24/09
|
Type
|
Free
|
Moderators jimr1717 mrwrn2010 NASDAQ2020 IB_ namtae Dr JoeBarducci |
Elite needs a Board of Directors that represents all shareholders !!!
Senior Moderator: IB_
Posted: 6/5/23
________________________________________________________________________________________________________________
Elite Pharmaceuticals, Inc. |
Website | Location | Employees | Facility | CEO |
www.elitepharma.com | Northvale, New Jersey | 53 | 55,000 sq ft | Nasrat Hakim |
Products & Pipeline | ||||
Drug | Market Size | Status | Competitors | Marketed By |
Adderall IR | 389.8 M | On Market | 15 | Elite |
Adderall XR | 1.56 B | On Market | 10 | Elite & Prasco |
Dantrolene | 6.3 M | On Market | 2 | Elite |
Isradipine | 5.5 M | On Market | 1 | Elite |
Loxapine | 5 M | On Market | 2 | Elite |
Phendimetrazine | 4.5 M | On Market | 4 | Elite |
Trimipramine | 2 M | On Market | 1 | Elite |
Naltrexone | 16 M | On Market | 5 | Precision Dose |
Phentermine Capsules | 7.5 M | On Market | 6 | Precision Dose |
Phentermine Tablets | 40 M | On Market | 8 | Precision Dose |
Vigabatrin | 233.7 M | On Market | 13 | Pyros |
Doxycycline | 85 M | Approved (Discontinued) | 9 | ---------- |
Tylenol with Codeine | 45 M | Approved (On Hold - Opioid) | 5 | ---------- |
Dopamine Agonist | 12 M | Filed with FDA - 22 Dec 2022 | ---------- | ---------- |
Methotrexate | 64.3M | Appoved - 16 May 2024 | 8 | Elite |
OxyContin | 720 M | Filed with FDA - 17 Aug 2023 | ---------- | ---------- |
Vyvanse | 5.1 B | Filed with FDA - 21 Dec 2023 | 14 | ---------- |
Concerta | 1.16 B | In Development (Final Stages) | 9 | ---------- |
Financials | ||||
Fiscal Year | Revenue | Change | Net Income | Change |
2019 | 7,568,508 | ---------- | (9,279,321) | ---------- |
2020 | 17,994,639 | +137.76% | (2,240,351) | +75.86% |
2021 | 25,380,749 | +41.05% | 5,088,421 | +327.13% |
2022 | 32,262,117 | +27.11% | 8,898,245 | +74.87% |
2023 | 34,155,114 | +5.87% | 3,561,846 | -59.97% |
2024 Q1 | 8,980,076 | +17.04% | 1,141,809 | +273.28% |
2024 Q2 | 14,157,185 | +64.90% | 14,934,601 | +866.0% |
2024 Q3 | 15,538,800 | +68.00% | 3,500,000 | +80.0% |
FY 2024 Projected | Minimum Projected: 50,000,000 | Minimum YOY Projected Increase of 68.31% | ||
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |